Perfecting Placement of PARPs: Preventing Progression of Ovarian Cancer
In the fast paced world of PARP inhibitor approvals in both the setting of maintenance and therapy in ovarian cancer, this panel of experts will assist practitioners to understand how to order germline and somatic testing for BRCA and HRD mutations. Speakers will discuss sequencing of PARP inhibitors as well as mitigating side effects. Additionally, they will discuss future directions for the use of PARP inhibitors as well as briefly discuss resistance to PARP inhibitors.
Speakers:
Premal Thaker, MD, MS
Washington University in St. Louis Siteman Cancer Center
Mary (“Maggie”) Mullen, MD
Washington University in St. Louis School of Medicine
John Farley, MD, COL, FACOG, FACS
Dignity Health - Cancer Institute, St. Joseph's Hospital and Medical Center
Todd Tillmanns, MD, FACOG
West Cancer Center
Keywords: Ovarian, Ovary, PARP, PARPi, Maintenance therapy, Toxicity, future applications
This is an educational resource produced through collaboration between the Society of Gynecologic Oncology (SGO) and the Cancer Association of Community Cancer Centers (ACCC).
This activity is supported by independent medical education grants from AstraZeneca and Merck.
Target Audience
Physicians, Trainees, Residents, Fellows, APPs
Available Credit
- 0.50 AMA PRA Category 1 Credit™
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Society of Gynecologic Oncology (SGO). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Amedco LLC designates this Live material for a maximum of 0.50 Live AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. - 0.50 AMA PRA Category 1 Credits™- For Non-physicians
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Society of Gynecologic Oncology (SGO). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PAs may claim a maximum of 0.50 Live Category 1 credits for completing this activity. - 0.50 Attendance
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Society of Gynecologic Oncology (SGO). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Amedco LLC designates this activity for a maximum of 0.50 Live knowledge-based CPE contact hours. - 0.50 CNE Contact Hours
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Society of Gynecologic Oncology (SGO). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Amedco LLC designates this activity for a maximum of 0.50 Live ANCC contact hours.